Search - tctmd.com

Displaying 1 - 7 of 7

Sort: Relevancy | Date

Presentation ACC 2025

Clopidogrel versus Aspirin Monotherapy in Patients with High Ischemic Risk after PCI: SMART-CHOICE 3 Trial

Presenter: Joo-Yong Hahn

March 29, 2025

Presentation ACC 2020

The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: COMPASS Diabetes

Presenter: Deepal L. Bhatt

March 30, 2020

Presentation ACC 2020

Ticagrelor With or Without Aspirin in Acute Coronary Syndrome After PCI: Randomized Evaluation Of Ticagrelor Monotherapy After 3- month Dual-antiplatelet Therapy In Acute Coronary Syndrome The TICO trial

Presenter: Yangsoo Jang

March 30, 2020

Presentation ACC 2019

Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial

Presenter: Renato Lopes

March 18, 2019

Presentation ACC 2017

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

Presenter: Magnus Ohman

March 27, 2017

Presentation ACC 2017

EINSTEIN CHOICE: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Presenter: Jeff Weitz

March 20, 2017

Presentation ACC 2015

Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Presenter: Marc S. Sabatine

March 14, 2015

Advertisement

Clopidogrel versus Aspirin Monotherapy in Patients with High Ischemic Risk after PCI: SMART-CHOICE 3 Trial

The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: COMPASS Diabetes

Ticagrelor With or Without Aspirin in Acute Coronary Syndrome After PCI: Randomized Evaluation Of Ticagrelor Monotherapy After 3- month Dual-antiplatelet Therapy In Acute Coronary Syndrome The TICO trial

Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

EINSTEIN CHOICE: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content